메뉴 건너뛰기




Volumn 9, Issue 3, 2003, Pages 289-292

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis

Author keywords

Multiple sclerosis; Prognosis; Risk factors; Sample size

Indexed keywords

IMMUNOMODULATING AGENT;

EID: 0037645916     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms910oa     Document Type: Article
Times cited : (7)

References (27)
  • 1
    • 0033821045 scopus 로고    scopus 로고
    • Short-term prognosis in early relapsing-remitting multiple sclerosis
    • Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 2000; 55: 689-693.
    • (2000) Neurology , vol.55 , pp. 689-693
    • Scott, T.F.1    Schramke, C.J.2    Novero, J.3    Chieffe, C.4
  • 2
    • 0029873865 scopus 로고    scopus 로고
    • Long-term and short-term outcome of multiple sclerosis. A 3-year follow-up study
    • Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis. A 3-year follow-up study. Arch Neurol 1996; 53: 353-58.
    • (1996) Arch Neurol , vol.53 , pp. 353-358
    • Weinshenker, B.G.1    Issa, M.2    Baskerville, J.3
  • 3
    • 0025774940 scopus 로고
    • The natural history of multiple sclerosis: A geographically based study: 3. Multivariate analysis of predictive factors and models of outcome
    • Weinshenker BG, Rice GP, Noseworthy JH, Carriere W et al. The natural history of multiple sclerosis: A geographically based study: 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-56.
    • (1991) Brain , vol.114 , pp. 1045-1056
    • Weinshenker, B.G.1    Rice, G.P.2    Noseworthy, J.H.3    Carriere, W.4
  • 4
    • 0032788240 scopus 로고    scopus 로고
    • Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors
    • Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148-52.
    • (1999) J Neurol Neurosurg Psychiatry , vol.67 , pp. 148-152
    • Hawkins, S.A.1    McDonnell, G.V.2
  • 5
    • 0038263335 scopus 로고
    • Power
    • In Howell DC ed; Boston, Massachusetts: PWS Publishers
    • Howell DC. Power. In Howell DC ed. Statistical Methods for Psychology. Boston, Massachusetts: PWS Publishers, 1982: 151-70.
    • (1982) Statistical Methods for Psychology , pp. 151-170
    • Howell, D.C.1
  • 6
    • 4243714651 scopus 로고    scopus 로고
    • Risk factors for progression in early relapsing-remitting MS
    • Abstract P-411
    • Scott TS, Shramke CJ. Abstract P-411. Risk factors for progression in early relapsing-remitting MS. Mult Scler 2001; 7(Suppl 1): S121.
    • (2001) Mult Scler , vol.7 , Issue.SUPPL. 1
    • Scott, T.S.1    Shramke, C.J.2
  • 7
    • 0034564732 scopus 로고    scopus 로고
    • Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis
    • Bergamaschi R, Romani A, Tonietti S, Citterio A et al. Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis. Neurol Sci 2000; 21: S819-S823.
    • (2000) Neurol Sci , vol.21
    • Bergamaschi, R.1    Romani, A.2    Tonietti, S.3    Citterio, A.4
  • 8
    • 0020686503 scopus 로고
    • New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
    • Poser CM, Paty DW, Scheinberg L, McDonald WI et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
    • (1983) Ann Neurol , vol.13 , pp. 227-231
    • Poser, C.M.1    Paty, D.W.2    Scheinberg, L.3    McDonald, W.I.4
  • 9
    • 0021035886 scopus 로고
    • Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
    • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
    • (1983) Neurology , vol.33 , pp. 1444-1452
    • Kurtzke, J.F.1
  • 10
    • 0000263693 scopus 로고    scopus 로고
    • Exacerbation recovery and the progression of multiple sclerosis
    • Lublin FD, Cutter GR, Baier M. Exacerbation recovery and the progression of multiple sclerosis. Neurology 2000; 54(Suppl 3): A216-17.
    • (2000) Neurology , vol.54 , Issue.SUPPL. 3
    • Lublin, F.D.1    Cutter, G.R.2    Baier, M.3
  • 11
    • 0034676548 scopus 로고    scopus 로고
    • Relapses and progression of disability in multiple sclerosis
    • Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-38.
    • (2000) N Engl J Med , vol.343 , pp. 1430-1438
    • Confavreux, C.1    Vukusic, S.2    Moreau, T.3    Adeleine, P.4
  • 12
    • 0000784055 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
    • Abstract
    • Goodkin DE, North American Study Group. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54 2352 Abstract.
    • (2000) Neurology , vol.54 , pp. 2352
    • Goodkin, D.E.1
  • 13
    • 0035849496 scopus 로고    scopus 로고
    • Randomized controlled trial of interferon-beta-1a in secondary progressive MS
    • Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001; 56: 1496-1504.
    • (2001) Neurology , vol.56 , pp. 1496-1504
  • 14
    • 4243226828 scopus 로고    scopus 로고
    • Aspects of multiple sclerosis that relate to clinical trial design and treatment
    • In Rudick, RA, and Goodkin, DE ed; Malden, MA: Blackwell Science Inc.
    • Rudick RA, Goodkin DE. Aspects of multiple sclerosis that relate to clinical trial design and treatment. In Rudick, RA, and Goodkin, DE ed. Multiple Sclerosis Therapeutics Malden, MA: Blackwell Science Inc., 1999.
    • (1999) Multiple Sclerosis Therapeutics
    • Rudick, R.A.1    Goodkin, D.E.2
  • 15
    • 0037161296 scopus 로고    scopus 로고
    • Randomized controlled trials to assess therapies for multiple sclerosis
    • Wingerchuck DM, Noseworthy JH. Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002; 58(Suppl 4): S40-48.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 4
    • Wingerchuck, D.M.1    Noseworthy, J.H.2
  • 16
    • 0035058217 scopus 로고    scopus 로고
    • A prospective, open-label treatment trial to compare the effect of IFN β-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
    • Kahn OA, Tselis AC, Kamholz JA, Garbern JY et al. A prospective, open-label treatment trial to compare the effect of IFN β-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8: 141-48.
    • (2001) Eur J Neurol , vol.8 , pp. 141-148
    • Kahn, O.A.1    Tselis, A.C.2    Kamholz, J.A.3    Garbern, J.Y.4
  • 17
    • 0035091667 scopus 로고    scopus 로고
    • The European/Canadian multicenter, double blind, randomized, placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
    • Comi G, Filippi M, Wolinsky JS and European/Canadian Glatiramer Acetate Study Group. The European/Canadian multicenter, double blind, randomized, placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-97.
    • (2001) Ann Neurol , vol.49 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 18
    • 0023248694 scopus 로고
    • A pilot of cop 1 in exacerbating-remitting multiple sclerosis
    • Bornstein MB, Miller A, Slagle S, Weitzman M et al. A pilot of cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14.
    • (1987) N Engl J Med , vol.317 , pp. 408-414
    • Bornstein, M.B.1    Miller, A.2    Slagle, S.3    Weitzman, M.4
  • 19
    • 0035170089 scopus 로고    scopus 로고
    • Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis
    • Whitaker JN, Wolinsky JS, Narayana PA, Bartolucci AA et al. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol 2001; 58: 49-54.
    • (2001) Arch Neurol , vol.58 , pp. 49-54
    • Whitaker, J.N.1    Wolinsky, J.S.2    Narayana, P.A.3    Bartolucci, A.A.4
  • 20
    • 0035845431 scopus 로고    scopus 로고
    • Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis
    • Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T et al. Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-57.
    • (2001) Neurology , vol.57 , pp. 853-857
    • Fazekas, F.1    Strasser-Fuchs, S.2    Kollegger, H.3    Berger, T.4
  • 21
    • 0035196870 scopus 로고    scopus 로고
    • Oligoclonal band number as a marker for prognosis in multiple sclerosis
    • Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58: 2044-45.
    • (2001) Arch Neurol , vol.58 , pp. 2044-2045
    • Avasarala, J.R.1    Cross, A.H.2    Trotter, J.L.3
  • 22
    • 0033586376 scopus 로고    scopus 로고
    • Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis
    • Kappos L, Moeri D, Radue EW, Schweikert K et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Lancet 1999; 353: 964-69.
    • (1999) Lancet , vol.353 , pp. 964-969
    • Kappos, L.1    Moeri, D.2    Radue, E.W.3    Schweikert, K.4
  • 23
    • 0027225525 scopus 로고
    • Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions
    • Smith ME, Stone LA, Albert PS, Frank JA et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33: 480-89.
    • (1993) Ann Neurol , vol.33 , pp. 480-489
    • Smith, M.E.1    Stone, L.A.2    Albert, P.S.3    Frank, J.A.4
  • 24
    • 0007949236 scopus 로고    scopus 로고
    • Correlations of baseline MRI burden of disease and lesion activity with subsequent activity: Implications for future MS therapeutic trial
    • Zhao GJ, Li DKB, Wang ZY, Cheng Y, Paty DW and the UBC MSMRI Research Group. Correlations of baseline MRI burden of disease and lesion activity with subsequent activity: Implications for future MS therapeutic trial. Neurology 1999; 52 (Suppl 2): P04.109.
    • (1999) Neurology , vol.52 , Issue.SUPPL. 2
    • Zhao, G.J.1    Li, D.K.B.2    Wang, Z.Y.3    Cheng, Y.4    Paty, D.W.5
  • 25
    • 0028815032 scopus 로고
    • 2-weighted brain MRI activity in multiple sclerosis: A follow-up study
    • 2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology 1995; 45: 255-60.
    • (1995) Neurology , vol.45 , pp. 255-260
    • Filippi, M.1    Paty, D.W.2    Kappos, L.3    Barkhof, F.4
  • 26
    • 0037122957 scopus 로고    scopus 로고
    • A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
    • Brex PA, Ciccarelli O, O'Riordan JI, Sailer M. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2001; 346: 158-64.
    • (2001) N Engl J Med , vol.346 , pp. 158-164
    • Brex, P.A.1    Ciccarelli, O.2    O'Riordan, J.I.3    Sailer, M.4
  • 27
    • 0035960564 scopus 로고    scopus 로고
    • Sample size estimations for MRI monitored trials of MS comparing new vs. standard treatments
    • Sormani MP, Rovaris M, Bagnato F, Molyneux P et al. Sample size estimations for MRI monitored trials of MS comparing new vs. standard treatments. Neurology 2001; 57: 1883-85.
    • (2001) Neurology , vol.57 , pp. 1883-1885
    • Sormani, M.P.1    Rovaris, M.2    Bagnato, F.3    Molyneux, P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.